Form 4: Jaguar Health Officer Granted Equity Awards

Jaguar Health's Chief of Sustainable Supply, Steven R. King, received grants of 11,740 restricted stock units and 11,740 stock options.

Summary

• Steven R. King, an officer and director of Jaguar Health, Inc. (JAGX), was granted 11,740 shares of common stock in the form of restricted stock units (RSUs) and 11,740 stock options.
• The grants were approved by the issuer's board of directors on December 11, 2025, under the company's 2014 Stock Incentive Plan.
• Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock.
• The restricted stock units are scheduled to vest on December 11, 2026, with vested shares to be delivered on that date.
• The stock options have an exercise price of $1.44 per share and will vest ratably on a monthly basis over 12 months from the grant date (December 11, 2025), contingent on continued employment.
• The stock options have an expiration date of December 11, 2035.
• Following these transactions, Steven R. King beneficially owns 11,885 shares of common stock directly and 11,740 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity grants align management's interests with shareholders, promoting long-term commitment and performance, which is generally viewed favorably.

Positives

• The equity grants align the interests of Steven R. King, a key officer and director, with those of the shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for both RSUs and stock options encourage continued employment and commitment to the company's success over a defined period.

Negatives

• The issuance of new shares upon vesting and exercise of options could lead to a minor dilutive effect on existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• The value of the granted restricted stock units and stock options is subject to the future market price fluctuations of Jaguar Health, Inc.'s common stock.
• The vesting of both the RSUs and options is contingent upon Steven R. King's continued employment with the issuer, meaning forfeiture could occur if employment terminates before vesting.

Future Outlook

The equity grants, with their vesting schedules extending into December 2026 and option expiration in December 2035, indicate an expectation of Steven R. King's continued long-term commitment and contribution to Jaguar Health, Inc.'s strategic objectives.

Industry Context

Equity compensation, including restricted stock units and stock options, is a widely adopted practice across various industries, particularly in the biotechnology and pharmaceutical sectors, to attract, retain, and incentivize key executives and align their performance with shareholder returns.

Comparison to Industry Standards

• Equity grants under incentive plans are a standard industry practice for executive compensation, aiming to align management interests with shareholder value. This filing does not provide specific comparable company or project data.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting and exercise of equity awards, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees (specifically Steven R. King): Receives significant equity compensation, incentivizing continued employment and performance.

Next Steps

• The restricted stock units are scheduled to vest on December 11, 2026.
• The stock options will vest ratably on a monthly basis over 12 months from December 11, 2025, contingent on continued employment.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to an executive, which is a standard compensation practice. While it indicates management's continued commitment, it does not present new fundamental information that would typically warrant a change in investment recommendation. The potential for minor dilution is offset by the alignment of executive and shareholder interests. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific transaction.

Keywords

Jaguar Health, JAGX, Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, Executive Compensation, Stock Incentive Plan, Corporate Governance